Rosiglitazone Versus Placebo in Chronic Stable Angina
Status:
Terminated
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
We wish to see if the drug rosiglitazone, currently used in the treatment of type 2 diabetes,
could be used as a new treatment for angina when compared with placebo in overweight subjects
who do not have overt diabetes. The drug will be given for 3 months and the subjects will be
have their angina tested, by way of exercise testing, angina quality of life questionnaire
and 24-hour ECG monitoring before and after using the drug.